Pharming (PHAR) Gains from Investment Securities (2019 - 2021)
Pharming (PHAR) posted Gains from Investment Securities of -$24113.8 for Q4 2021, up 85.07% on a QoQ basis from -$161562.4 in Q3 2021, and down 11.52% year-over-year from -$27252.5 in Q4 2020.
Pharming (PHAR) Gains from Investment Securities (2019 - 2021) Analysis & Trends
Pharming's Gains from Investment Securities history runs 3 years deep, the most recent figure standing at -$24113.8 for Q4 2021.
- Quarterly Gains from Investment Securities fell 11.52% year-over-year to -$24113.8 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was -$207299.5 (changed N/A YoY) and the FY2021 annual result came in at -$25.0 million, down 120544.73% from the prior year.
- Gains from Investment Securities was -$24113.8 for Q4 2021 at Pharming, up from -$161562.4 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at -$21623.4 in Q4 2020 and bottomed at -$19.5 million in Q4 2019.
- A 3-year average of -$4.9 million and a median of -$92838.1 in 2021 frame the typical range for Gains from Investment Securities.
- Annual changes were most pronounced in 2020 — Gains from Investment Securities surged 99.89% — and 2021, when it decreased 11.52%.
- Pharming's Gains from Investment Securities stood at -$19.5 million in 2019, then jumped by 99.89% to -$21623.4 in 2020, then declined by 11.52% to -$24113.8 in 2021.
- Business Quant data shows PHAR's Gains from Investment Securities at -$24113.8 in Q4 2021, -$161562.4 in Q3 2021, and -$21623.4 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 471.84 Bn | 467.05 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.01 Bn | 61.26 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - |
| 8 | Argenx Se | 55.93 Bn | 50.74 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn |
| 10 | Pharming | 8.96 Bn | 8.91 Bn | 65.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | -24,113.76 |
| Dec 31, 2021 | -24,113.76 |
| Sep 30, 2021 | -161,562.36 |
| Sep 30, 2021 | -161,562.36 |
| Dec 31, 2020 | -21,623.37 |
| Dec 31, 2020 | -21,623.37 |
| Dec 31, 2019 | -19.52 Mn |
| Dec 31, 2019 | -19.52 Mn |